주 메뉴 바로가기 본문 바로가기 하단 바로가기

Company

Leading the Korean pharmaceutical industry

The dawn of legendary boldness and creativity Jung-Jin Seo, the company chairman, first founded Nexol in 2000 to examine diverse business opportunities. Seo established Celltrion in 2002 and began to research the resources for production facilities for biopharmaceuticals.

Oct. 2001
Signed the MOU on the creation of a joint venture company
Feb. 2002
Foundation of Celltrion

Solidifying The Basis for Growth From 2003 to 2008, Celltrion continued to grow and consolidate its basis for pioneering uncharted territories and achieving growth.
The company conquered the numerous challenges it encountered in the process.

Jun. 2005
Supply agreement with BMS(Bristol-Myers Squibb)
Jul. 2005
Mechanical completion of Plant 1(50,000L)
Dec. 2007
Plant 1 receives cGMP facility approval by the US FDA
Aug. 2008
Initial Public Offering(IPO)

Opening the Era of Biosimilars In May 2013, the world’s first antibody biosimilar, Remsima, was approved by the EMA, signaling the start of Celltrion’s global expansion.
The company established its second plant, further augmenting its production capacity, to ensure a stable supply around the world.

May. 2010
Secured significant investment from
Temasek Holdings, Singapore
Oct. 2011
Mechanical completion of Plant 2(90,000L)
Jul.2012
Remsima is approved by Korea (MFDS)
Apr. 2013
Begins global clinical trial of CT-P27
Aug. 2013
Remsima is approved by Europe (EMA)
Jan. 2014
Herzuma is approved by Korea (MFDS)
Feb. 2014
Begins clinical trial phase 2a of CT-P27

Securing A Path of Accelerated Growth In 2016, Celltrion also obtained approval by the FDA on the distribution of Remsima in the United States, thereby gaining stability in the land of new opportunities.
Celltrion continues to lead the development of innovative treatments and technologies, including new drugs, vaccines, and biobetters, transforming itself into a world-renowned provider of a comprehensive range of biotechnology and engineering solutions.

Mar. 2015
Introduced a new management system
with professional executives.
Jun. 2015
Plant 1 and Plant 2 receive approval from the FDA
of US. on all cGMP manufacturing facilities
Apr. 2016
Remsima is approved by US (FDA)
Oct. 2016
Reached KRW 1 trillion in cumulative Remsima exports
Nov. 2016
Truxima is approved by Korea (MFDS)
Remsima begins sales in US
Dec. 2016
Begins clinical trial phase 2b of CT-P27
Feb. 2017
Truxima is approved by Europe (EMA)
Jul. 2017
Begins clinical trial phase 1 of CT-P16
Feb. 2018
Listed on KOSPI
Herzuma is approved by Europe (EMA)
May. 2018
Signed an agreement with Yonsei University Health
System on the joint development and licensing-in
of treatment for ischemic strokes
Aug. 2018
Begins clinical trial phase 1ㆍ3 of CT-P17
Begins clinical trial phase 3 of CT-P16
Sep. 2018
Signed an agreement with Emory University on
supporting the research and development
of a new drug for atherosclerosis
Nov. 2018
Temixys is approved by US (FDA)
Truxima is approved by US (FDA)
Dec. 2018
Herzuma is approved by US (FDA)
Designated as a long-term supplier for the international
HIV treatment procurement prog
Jan. 2019
Filed global patent application on RemsimaSC
Mar. 2019
Signed an exclusive distribution agreement on CT-G20,
a treatment for hypertrophic cardiomyopathy, in Japan
Apr. 2019
Signed an agreement with iProgen Biotech on the joint
development of a new ADC drug based on ADED platform
Linezolid is approved by US (FDA)
May. 2019
Mehcanical completion of the expansion of Plant 1
(additional 50,000 L)
Nov.2019
RemsimaSC is approved by Europe (EMA)